Peter McGuffin Selected Research

Nortriptyline (Aventyl)

1/2019	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
1/2019	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder.
10/2018	Genetic disposition to inflammation and response to antidepressants in major depressive disorder.
1/2016	Combining clinical variables to optimize prediction of antidepressant treatment outcomes.
12/2014	An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
2/2013	Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.
12/2012	Self-report and clinician-rated measures of depression severity: can one replace the other?
11/2012	Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression.
10/2012	Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder.
4/2011	Changes in body weight during pharmacological treatment of depression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter McGuffin Research Topics

Disease

26	Major Depressive Disorder (Major Depressive Disorders) 01/2020 - 04/2009
14	Bipolar Disorder (Manic Depressive Psychosis) 01/2021 - 09/2008
12	Schizophrenia (Dementia Praecox) 01/2018 - 01/2002
8	Depressive Disorder (Melancholia) 05/2014 - 03/2009
5	Inflammation (Inflammations) 10/2018 - 02/2013
4	Genetic Risk Score 10/2018 - 01/2014
4	Mood Disorders (Mood Disorder) 10/2018 - 01/2007
4	Obesity 01/2017 - 11/2009
3	Drug-Related Side Effects and Adverse Reactions 11/2021 - 09/2009
3	Weight Gain 07/2011 - 09/2009
2	Mental Disorders (Mental Disorder) 01/2019 - 12/2003
2	Sleep Initiation and Maintenance Disorders (Insomnia) 07/2011 - 09/2009
2	Body Weight (Weight, Body) 04/2011 - 11/2009
2	Neurobehavioral Manifestations 12/2010 - 03/2009
2	Psychotic Disorders (Schizoaffective Disorder) 10/2010 - 04/2009
1	Anorexia Nervosa 01/2019
1	Anhedonia 01/2018
1	Dizziness (Lightheadedness) 07/2015
1	Neuralgia (Stump Neuralgia) 01/2014
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2014
1	Huntington Disease (Huntington's Disease) 11/2012
1	Tobacco Use Disorder (Nicotine Dependence) 09/2012
1	Cognitive Dysfunction 04/2012
1	Glaucoma 01/2012
1	Open-Angle Glaucoma (Glaucoma, Open Angle) 01/2012
1	Alcoholism (Alcohol Abuse) 10/2011
1	Migraine Disorders (Migraine) 06/2011
1	Weight Loss (Weight Reduction) 04/2011
1	Overweight 11/2009
1	Constipation 09/2009
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 11/2004

Drug/Important Bio-Agent (IBA)

20	Antidepressive Agents (Antidepressants)IBA 11/2021 - 09/2009
17	Escitalopram FDA Link 01/2019 - 03/2009
17	Nortriptyline (Aventyl)FDA LinkGeneric 01/2019 - 03/2009
8	Biological ProductsIBA 01/2021 - 01/2002
5	Brain-Derived Neurotrophic Factor (BDNF)IBA 05/2015 - 01/2007
4	Pharmaceutical PreparationsIBA 11/2021 - 12/2003
4	CytokinesIBA 01/2014 - 02/2013
3	C-Reactive ProteinIBA 10/2018 - 12/2014
3	Biomarkers (Surrogate Marker)IBA 12/2014 - 06/2011
3	Messenger RNA (mRNA)IBA 05/2014 - 02/2013
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020 - 08/2013
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2019 - 12/2014
2	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 01/2019 - 04/2011
2	catechol (pyrocatechol)IBA 01/2017 - 01/2007
2	TransferasesIBA 01/2017 - 01/2007
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 12/2014 - 01/2012
2	Glutamate Receptors (Glutamate Receptor)IBA 07/2014 - 01/2014
2	Serotonin (5 Hydroxytryptamine)IBA 07/2013 - 01/2012
2	Oxidoreductases (Dehydrogenase)IBA 06/2011 - 10/2010
1	FurinIBA 01/2021
1	Complement C4 (Complement Component 4)IBA 01/2020
1	LipidsIBA 01/2019
1	Glycogen Synthase KinasesIBA 10/2018
1	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)IBA 01/2017
1	Histones (Histone)IBA 04/2016
1	DNA (Deoxyribonucleic Acid)IBA 02/2015
1	MicroRNAs (MicroRNA)IBA 07/2014
1	Vesicle-Associated Membrane Protein 2 (VAMP2)IBA 05/2014
1	Calcium Channels (Calcium Channel)IBA 02/2014
1	CalciumIBA 01/2014
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2014
1	RNA (Ribonucleic Acid)IBA 01/2014
1	Complementary DNA (cDNA)IBA 01/2014
1	Citalopram FDA LinkGeneric 09/2013
1	Lamotrigine (Lamictal)FDA LinkGeneric 07/2013
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 02/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2013
1	Tacrolimus Binding Proteins (FKBP)IBA 02/2013
1	InterleukinsIBA 02/2013
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 02/2013
1	IntegrinsIBA 11/2012
1	Nicotine FDA Link 09/2012
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 04/2012
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 04/2012
1	Protein Kinase CIBA 04/2012
1	P-2 (P 2)IBA 01/2012
1	GalaninIBA 10/2011
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 06/2011
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 06/2011
1	GABA-A Receptors (GABA(A) Receptor)IBA 10/2010
1	5,10-methylenetetrahydrofolic acidIBA 10/2010
1	DysbindinIBA 09/2009
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 04/2009
1	Indicators and Reagents (Reagents)IBA 04/2009
1	AnkyrinsIBA 09/2008
1	Methamphetamine (Desoxyn)FDA LinkGeneric 11/2004

Therapy/Procedure

4	Therapeutics 01/2018 - 06/2011
2	Drug Therapy (Chemotherapy) 10/2013 - 06/2011
1	Deep Brain Stimulation 01/2018